These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21449681)

  • 21. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
    Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
    Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
    Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
    Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
    Giovannetti E; Pacetti P; Reni M; Leon LG; Mambrini A; Vasile E; Ghidini M; Funel N; Lucchesi M; Cereda S; Peters GJ; Cantore M
    Pharmacogenomics; 2011 Dec; 12(12):1641-52. PubMed ID: 22026922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
    Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC
    Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.
    Brewster AM; Jorgensen TJ; Ruczinski I; Huang HY; Hoffman S; Thuita L; Newschaffer C; Lunn RM; Bell D; Helzlsouer KJ
    Breast Cancer Res Treat; 2006 Jan; 95(1):73-80. PubMed ID: 16319991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin.
    Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J
    Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
    Liu Y; Chen H; Chen L; Hu C
    Hepatogastroenterology; 2012 Jun; 59(116):977-80. PubMed ID: 22580644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
    Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
    Jun L; Haiping Z; Beibei Y
    Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.